Research Article

The Amount of Weight Loss Six Months after Bariatric Surgery: It Makes a Difference

Olga Nedeljkovic-Arsenovic^a Marko Banovic^{a, b} Dejan Radenkovic^{a, c}
Nemanja Rancic^d Snezana Polovina^{e, f} Dragan Micic^{a, e}
Ivana Nedeljkovic^{a, b}

^aSchool of Medicine, University of Belgrade, Belgrade, Serbia; ^bClinical Center of Serbia, Department of Cardiology, Belgrade, Serbia; ^cClinical Center of Serbia, Department of Digestive Surgery, Belgrade, Serbia; ^dCentre for Clinical Pharmacology, Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; ^eClinical Center of Serbia, Department of Endocrinology, Belgrade, Serbia; ^fFaculty of Pharmacy, University of Novi Sad, Novi Sad, Serbia

Keywords

Bariatric surgery · Cardiopulmonary exercise test · Roux-en-Y gastric bypass · Functional capacity

Abstract

Background: Bariatric surgery, especially Roux-en-Y gastric bypass (RYGB), has become the most frequently used therapy for morbid obesity. **Objectives:** The aim of this study was to examine the effects of surgically induced weight loss on cardiopulmonary function 6 months after the procedure, as well as the effect of such an intervention on well-known risk factors for cardiovascular diseases. **Methods:** This is a cross-sectional study on 66 morbidly obese patients (BMI ≥ 40 or ≥ 35 kg/m² with present comorbidities), comparing their cardiopulmonary function prior to and 6 months after RYGB surgery. **Results:** The substantial amount of weight loss (29.80 ± 13.27 kg) after RYGB surgery was associated with significant reduction of comorbidities, especially diabetes and sedentary lifestyle ($p = 0.005$ and $p = 0.002$, respectively). Regarding functional capacity, there was significant increase in peak oxygen uptake (VO₂ peak, $p = 0.003$), duration of exercise testing, metabolic equivalents (exercise time and METs, $p < 0.001$), and in peak O₂ pulse. These findings were particularly pronounced in a group of patients who had lost more than 18% of initial weight. **Conclusions:** Reduction of body weight after RYGB surgery is associated with significantly improved cardiorespiratory function

Olga Nedeljkovic-Arsenovic, MD, PhD student
Department of Cardiology
Faculty of Medicine, University of Belgrade, Dr Subotica 8
RS-11000 Belgrade (Serbia)
E-Mail olganedeljkovic@gmail.com

6 months after surgery, especially in patients who lost more than 18% of their initial body weight. In addition, substantial decreases in body weight were also associated with a reduction of cardiovascular risk factors such as diabetes, smoking, hypertriglyceridemia, and sedentary lifestyle.

© 2019 The Author(s)
Published by S. Karger AG, Basel

Introduction

Obesity is a leading public health problem in the 21st century [1]. It is a chronic disease caused by excessive fat accumulation in the body and weight gain leading to health disorders, poor quality of life, morbidity, and also it represents financial burden for the healthcare system, especially for developing countries like Serbia [2–5]. Obesity and being overweight are associated with increased total mortality, especially due to cardiovascular disease [6–9].

Roux-en-Y gastric bypass (RYGB) represents one of the most effective surgical options for surgical treatment of obesity [10]. In comparison with nonsurgical treatment, surgery results in more extensive body weight loss, higher remission rates of metabolic syndrome, and better control of comorbidities [8, 11–14]. The mortality rate after gastric bypass surgery is 0.3–1%, while the morbidity rate is 18.7% [13, 15, 16].

Morbid obesity is associated with cardiopulmonary function disorders and with increased risk of cardiovascular disease. Obesity can lead to structural and functional worsening of the cardiovascular and pulmonary system [17, 18], as well as a reduction of the oxidative capacity of skeletal muscles [19]. Cardiopulmonary functional capacity provides diagnostic and prognostic information in a wide variety of clinical settings [20, 21].

Whereas physical function has been demonstrated to improve within a couple of weeks after bariatric surgery [22], cardiopulmonary functional capacity has not been thoroughly evaluated and compared before and 6 months after bariatric surgery [23–25].

The aim of this study was to examine if significant weight loss that occurs after bariatric surgery is associated with improved cardiopulmonary functional capacity 6 months after the surgical procedure, and if surgically induced weight loss has an effect on existing cardiovascular risk factors.

Materials and Methods

Type of Study

This is a retrospective cross-sectional study on 96 patients who scheduled for bariatric surgery. Of them, 66 patients fulfilled inclusion and exclusion criteria and were selected for a 6-month follow-up after surgery. All patients underwent cardiopulmonary exercise testing (CPET) before and 6 months after surgical treatment.

Study Participants

A total of 66 morbidly obese patients (body mass index [BMI] ≥ 40 or ≥ 35 kg/m² with obesity-related health conditions) aged between 20 and 61 years, mostly women (77.3%), who underwent bariatric surgery were participants of our study. Functional evaluation was performed prior and 6 months after RYGB. All patients were examined at the Clinical Center of Serbia in the Laboratory for CPET. All patients who fulfilled inclusion and exclusion criteria were included after providing signed informed consent (Fig. 1).

Fig. 1. Flow chart of inclusion and exclusion criteria.

Cardiopulmonary Exercise Testing

The cardiopulmonary stress test was done on a treadmill using the maximal Bruce protocol with simultaneous breath-by-breath analysis of exchanged gases in the exhaled air through a facial mask. Each patient performed the same test protocol before and after RYGB. All patients had a normal electrocardiogram (ECG) before the test. During stress testing, 12 channel ECG, oxygen uptake (VO_2) at the first anaerobic threshold (determined according to the V-slope method), as well as peak oxygen uptake (peak VO_2) were evaluated. Ventilation parameters and breathing reserve were also monitored. Blood pressure and heart rate were measured at the beginning of the stress test, at the end of each loading level, and during recovery. None of the patients had a positive stress test for myocardial ischemia. The CPET was considered maximal when the ratio of carbon dioxide production (VCO_2) to oxygen consumption (VO_2) at the end of the test ($\text{VCO}_2/\text{VO}_2 = \text{RER}$) was 1.1. After completing CPET, all patients underwent RYGB.

Statistical Analysis

Complete statistical analysis of data was done using the statistical software package, PASW Statistics 18® [SPSS [Hong Kong] Ltd., Hong Kong, China]. All variables were presented as frequency of certain categories. The χ^2 test was used for analyzing the significance of differences of categorical variables. Continuous variables were presented as means (M) and standard deviation (SD) and range and were compared using the paired samples t test and

Table 1. Anthropometric measures of patients before surgery and 6 months after surgery

	Before surgery (A)	Six months after surgery (B)	<i>p</i> value*	Amount of reduction 6 months after surgery (A–B)
BM, kg	126.92±19.19	97.12±17.28	<0.001	29.80±13.27
BSA, m ²	2.31±0.21	2.06±0.20	<0.001	0.25±0.12
BMI, kg/m ²	43.75±5.22	33.78±6.01	<0.001	9.96±4.25

Values are given as mean ± SD. BM, body mass; BSA, body surface area; BMI, body mass index. * Paired samples *t* test.

Table 2. Patient distribution before and after surgery according to comorbidities and therapy

	Before surgery	Six months after surgery	<i>p</i> value*
<i>Comorbidities</i>			
Physical activity	23 (34.8)	42 (63.6)	0.002
Hypertension	29 (43.9)	27 (40.9)	0.860
COPD	1 (1.5)	2 (3.1)	0.978
OSA	2 (3.0)	–	0.932
DM/IR	18 (27.3)/6 (9.1)	9 (14.1)/–	0.005
Hypercholesterolemia	6 (9.1)	7 (10.6)	1.000
Hypertriglyceridemia	6 (9.1)	2 (3.1)	0.294
Smoking	14 (21.2)	9 (14.1)	0.285
<i>Therapy</i>			
Antihypertensive therapy	26 (39.4)	26 (39.4)	1.000
Beta-blockers	16 (24.2)	19 (28.8)	0.518
Ca antagonist	11 (16.7)	6 (9.4)	0.331
Nitrates	1 (1.5)	–	–
ACE inhibitors	17 (25.8)	10 (15.6)	0.227
Statins	5 (7.6)	–	–
Antidiabetics	24 (36.4)	9 (14.1)	0.007

Values are given as *n* (%). COPD, chronic obstructive pulmonary disease; OSA, obstructive sleep apnea syndrome; DM, diabetes mellitus; IR, insulin resistance; ACE inhibitors, angiotensin-converting-enzyme inhibitors; Ca antagonist, calcium channel blockers. * χ^2 test.

independent *t* test. Distribution normality was tested using the Kolmogorov-Smirnov test (the number of subjects was >50). The level of the statistical significance was estimated at *p* < 0.05 for all analyses.

Results

Anthropometric measures of the group before and after surgery are presented in Table 1. There was a statistically significant reduction of body mass weight (BM), body surface area (BSA), and BMI 6 months after surgery in comparison to the initial values (*p* < 0.001).

Most of the 66 patients had class III obesity (BMI > 40 kg/m²; *n* = 48 or 72.7%) and the remainder had class II obesity (BMI 35–39.99 kg/m²; *n* = 17 or 25.8%). Comorbidities related to obesity in those patients were hypertension in 43.9% patients, diabetes mellitus (DM) in

Table 3. Distribution of patients according to the decrease of body mass (<18% and >18%) before surgery versus 6 months after bariatric surgery

	<18% BM			>18% BM			Before surgery	Six months after surgery
	before surgery	6 months after surgery	p value*	before surgery	6 months after surgery	p value*	<18% BM / >18% BM p value**	<18% BM / >18% BM p value**
FEV1, L	3.15±0.65	3.38±0.71	0.052	2.94±0.57	3.66±3.43	0.146	0.232	0.745
FEV1, %	97.50±12.30	100.44±12.42	0.219	90.26±14.97	96.88±15.34	<0.001	0.085	0.403
Time to AT, s	258.75±104.62	314.37±131.55	0.055	248.33±92.93	396.04±123.30	<0.001	0.708	0.027
Ex time, s	398.81±109.59	446.94±114.08	0.028	361.82±99.33	517.70±127.68	<0.001	0.211	0.045
Peak VO ₂ , mL/kg/min	20.19±2.71	22.26±3.19	0.009	21.20±3.95	26.32±4.83	<0.001	0.345	0.003
METs	5.64±0.76	6.36±0.88	0.008	6.08±1.06	7.48±1.33	<0.001	0.160	0.003
Peak VO ₂ , mL/min	2.62±0.43	2.58±0.43	0.708	2.62±0.49	2.40±0.51	<0.001	0.955	0.174
HR at AT, beat/min	143.31±16.86	136.56±22.90	0.197	152.30±16.83	144.80±16.46	<0.006	0.068	0.120
Peak O ₂ pulse, mL/beat	17.76±3.82	17.75±3.96	0.996	17.21±4.43	14.87±3.03	<0.001	0.662	0.003
MaxSBP, mm Hg	182.19±18.11	165.31±23.57	0.054	183.70±28.15	164.30±24.97	<0.001	0.841	0.887
MaxDBP, mm Hg	101.44±8.95	94.69±9.59	0.010	97.56±12.05	92.58±10.24	<0.016	0.241	0.470
Max VE, L/min	69.28±12.97	63.87±18.79	0.213	67.36±12.92	63.18±15.77	<0.021	0.606	0.886
BR, %	37.94±11.51	42.13±10.93	0.174	35.84±14.68	41.70±12.09	<0.007	0.604	0.901
VE/VCO ₂ slope	26.18±5.07	23.82±2.63	0.080	26.96±4.75	24.79±4.14	<0.003	0.580	0.381
PETCO ₂ , mm Hg	36.25±5.30	34.76±3.87	0.788	36.91±4.91	31.48±4.46	<0.010	0.813	0.565
RER	1.02±0.07	1.07±0.06	0.035	1.01±0.07	1.07±0.06	<0.001	0.806	0.871

Values are given as mean ± SD. BM, body mass; FEV1, forced expiratory volume in the first second; Peak VO₂, oxygen uptake at maximal effort; AT, anaerobic threshold; EX time, exercise time; METs, metabolic equivalents of task; VE/VCO₂ slope, ventilatory efficiency; VE, minute ventilation; BR, breathing reserve; PETCO₂, partial pressure of end-tidal carbon dioxide; SBP, systolic blood pressure; DBP, diastolic blood pressure; RER, respiratory exchange ratio; HR at AT, heart rate at first anaerobic threshold. * Paired samples *t* test. ** Independent *t* test.

Fig. 2. Number of antihypertensive drugs before and 6 months after bariatric surgery.

27.3%, insulin resistance in 9.1%, and obstructive sleep apnea in 3.0%. Most patients were sedentary before surgery (65.2%). All patients with hypertension took antihypertensive therapy including angiotensin-converting enzyme inhibitors (ACE inhibitors) in 25.8%, beta-blockers in 24.2%, calcium channel blockers (Ca antagonists) in 16.7%, and nitrates in 1.5%. Furthermore, 36.4% of patients had oral therapy for DM. Six of the patients (9.1%) who underwent bariatric surgery had hypertriglyceridemia and hypercholesterolemia, 5 of them were taking statins before intervention.

With respect to the accompanying comorbidities, there was significant clinical improvement in DM and obstructive sleep apnea syndrome 6 months after surgery (Table 2). Most of the patients become more physically active (63.6%). In addition, there was a reduction

Fig. 3. Average of peak VO_2 in patients with bariatric surgery according to decrease of BM (<18 and >18%) before versus 6 months after bariatric surgery.

in the use of drugs for hypertension. Although the same number of patients (29 subjects) were using pharmacotherapy for hypertension after surgery, only 9 patients were using dual therapy. Before surgery, 11 patients were using dual therapy and 4 patients were using triple antihypertensive therapy (Fig. 2). Also, after surgery only 9 of 26 patients with preoperative DM continued to take medications for DM ($p = 0.007$). None of the patients continued to use statins after intervention.

Furthermore, we investigated the extent of weight loss that was associated with significant improvement in CPET parameters. Patients who lost more than 18% of their initial weight had significantly better CPET results 6 months after the surgery (Table 3). Comparing relative peak oxygen uptake (VO_2 peak/kg), there were important differences between the two groups ($p = 0.003$) after surgical treatment. In both groups, peak VO_2 per body weight was significantly increased after RYGB ($p = 0.009$ and $p < 0.001$, respectively) (Fig. 3). However, the absolute VO_2 peak was unchanged in those who had a <18% BM reduction, while there was a significant decrease in VO_2 peak after 6 months in those who had a >18% BM reduction ($p = 0.708$ and $p = 0.001$, respectively). In addition, exercise duration time was significantly longer in the group of patients who lost more than 18% of their initial weight. Also, ventilatory efficiency and breathing reserve were significantly better after surgery in patients with greater BM reduction (Table 3).

Discussion

In contrast to previous studies of cardiovascular outcomes after bariatric surgery [26, 27], which demonstrated physical capacity improvement on ergo bicycle, we have shown amelioration of cardiorespiratory functional parameters using a treadmill test. This is an important difference in study design, since walking is the most natural and most commonly reported mode of physical activity among patients. In general, in all patients, bariatric surgery brought certain improvement in cardiorespiratory function. Regarding the respiratory exchange ratio (RER), our study demonstrated significantly higher RER 6 months after surgery suggesting achievement of higher intensity of activity after greater loss of kilograms, but with no statistical difference among groups. This ratio was earlier reported in only three studies, showing an increase in two and no change in the other study [24, 25, 28].

However, our study is unique in that we suggest that an 18% reduction of initial weight after surgery is associated with statistically significant improvement in cardiorespiratory

parameters. Previous studies have also investigated CPET parameters 3–12 months after sleeve gastrectomy or gastric bypass surgery [11, 24, 29–31]. To our knowledge, this is the first study which has correlated the amount of weight loss that is needed to result in improvement of aerobic capacity. A study by MacMahon et al. [32] showed that weight loss of as little as 8 kg is associated with a significant decrease in left ventricular mass after 6 months, while Alpert et al. [33] demonstrated that cardiac function in morbidly obese individuals improved with an average weight loss of 55 kg. However, few studies performed a 6-min walk test for estimation of exercise capacity [34].

Peak VO_2 representing the highest achieved oxygen consumption during the cardiovascular stress test is the most often analyzed parameter for cardiorespiratory fitness assessment. A weight loss of 18% of initial kilograms after surgery was associated with significant differences between groups regarding relative oxygen consumption, suggesting improvement in aerobic capacity. However, more evidence is needed regarding mechanisms involved in that improvement. Improved aerobic capacity may be due to better efficiency in performing activities rather than real improvements in cardiorespiratory or muscle function. Even though an increase of VO_2 peak per body weight (mL/min/kg) confirmed better physical functioning and mobility [29–31], absolute aerobic capacity in terms of VO_2 peak (mL/min) was unchanged after bariatric surgery. Nevertheless, in the group which had more than 18% weight reduction, VO_2 peak (mL/min) was significantly reduced after surgery. Thus, improvement of physical functioning in patients after bariatric surgery is more a mechanical phenomenon of consequential weight loss than an absolute improvement of cardiopulmonary and muscle function [35]. Therefore, the risk of poor cardiorespiratory and muscle function may persist postsurgically in patients despite their weight loss.

According to preceding studies, the absolute VO_2 peak was unchanged (at the 12- and 27-month follow-up) [24, 25] or reduced (at the 6-month follow-up) [28] after bariatric surgery, which is similar to our findings. Peak VO_2 relative to body weight was importantly increased in all studies where it was reported [23–25, 28], but without indicating the amount of weight loss that is significant. In addition, in previous studies major postoperative increases in physical activity were seen after sleeve gastrectomy, and these findings were associated with greater weight loss and improved quality of life [36, 37]. The same outcome was observed in our study population but after RYGB surgery. About 64% of patients become physically active, as defined by having daily walks of a minimum of 1 h by self-report, so physical exercise pre- and postoperation might be recommended as a beneficial add-on therapy to bariatric surgery. Furthermore, we showed significant amelioration of peak O_2 pulse among groups after surgery. This result is different from previous reports in which peak O_2 pulse did not change 2 months after surgery [26, 27] and was not different between lean and obese individuals during treadmill exercise [24, 38]. Patients who had >18% weight reduction also had significant improvement in peak O_2 pulse compared to those with less weight reduction.

Abnormalities in exercise ventilation usually give useful explanation of pathophysiology of dyspnea, lung gas exchange, and control of ventilation. Currently, these types of measurements are recognized as meaningful indicators of disease severity and prognosis. In our study, we did not find differences among groups after surgery regarding ventilatory parameters. However, substantial weight loss should lead to an improvement in all ventilatory parameters including FEV1, breathing reserve, ventilatory efficiency, minute ventilation at peak exercise and PETCO_2 after 6 months. Similar to a study by Kanoupakis et al. [28], our study showed a decrease in minute ventilation at peak exercise ($p = 0.021$) 6 months after bariatric surgery that might be explained by mechanical facilitation in filling the lungs' alveoli after sufficient weight loss [39, 40]. Meanwhile, our data suggests that weight reduction of less than 18% is not associated with any statistically significant improvement of ventilatory function.

Our study has found that the substantial decrease of body weight and BMI that occurs after bariatric surgery is associated with a reduction of cardiovascular risk factors such as DM, smoking, hypertriglyceridemia, as well as on the sedentary lifestyle. In addition, the number of used drugs for DM and arterial hypertension was considerably reduced. From the perspective of the patients' quality of life, as well as from the economic point of view [3, 4, 41–43], this could be a very important finding. However, larger studies with higher number of patients are needed to further analyze these data. Nevertheless, we demonstrated that significant weight loss after RYGB improves daily physical activities and has a positive impact on accompanying comorbidities and existing cardiovascular risk factors [8, 9, 13, 16, 31, 44–46]. In addition to morbidity and premature mortality, obesity and physical inactivity are responsible for a large economic burden [47].

Conclusion

This study of cardiovascular and respiratory outcomes after bariatric surgery demonstrates the beneficial effects of surgical weight reduction on patients' health and functional capacity. In addition, we demonstrated that an 18% reduction of initial body weight may be a threshold value that is critical for significantly better aerobic capacity and other cardiorespiratory outcomes after bariatric surgery.

Limitations

The number of subjects evaluated is relatively small to assess patients based on age groups in terms of comparing VO_2 max. We did not perform echocardiographic evaluations in our study, and, as a result, we were unable to compare stroke volume and cardiac output before and after RYGB. Our study population was predominantly female, so future studies including male participants are needed to expand upon the current findings in order to better understand how bariatric surgery may impact cardiorespiratory capacity and exercise tolerance in men. It is known that VO_2 depends on sex, age, and physical fitness. We did not have a more adequate tool to measure physical activity in patients, such as by using an actigraphy device, and relied only on patient self-report.

Findings of this observational study should be confirmed by randomized controlled trials with a large sample size. Also, it is necessary to monitor these patients longer in order to evaluate the long-term effects of this surgical method on body weight loss, comorbidities, and quality of life.

Acknowledgement

The authors would like to express their gratitude to the Ministry of Education, Science and Technological Development of the Republic of Serbia for Grant No. 41022.

The authors would like to express their gratitude to Srdjan Nedeljkovic, MD, Assistant Professor at Harvard Medical School, Brigham and Women's Hospital, for critically reading the draft versions of this article, as well as for improving the English language.

Statement of Ethics

All patients have given their written informed consent. The study protocol has been approved by the local Ethical Committee on human research.

The principles of ICH Good Clinical Practice were strictly followed and ethical approval from the Ethics Committee of the Clinical Center Serbia was obtained for the study protocol under the number 318/6 on May 18th, 2017.

Disclosure Statement

The authors have no conflicts of interest to declare.

References

- 1 Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. *JAMA*. 2010 Jan;303(3):235–41.
- 2 World Health Organisation. The European health report 2015. Targets and beyond – Reaching new frontiers in evidence. Copenhagen: WHO Regional Office for Europe; 2015 [cited 2018 Feb 29]. Available from: http://www.euro.who.int/_data/assets/pdf_file/0006/288645/European-health-report-2015-full-book-en.pdf?ua=1.
- 3 Biorac N, Jakovljević M, Stefanović D, Perović S, Janković S. Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia. *Vojnosanit Pregl*. 2009 Apr;66(4):271–6. Serbian.
- 4 Jakovljevic M, Jovanovic M, Lazic Z, Jakovljevic V, Djukic A, Velickovic R, et al. Current efforts and proposals to reduce healthcare costs in Serbia. *Serb J Exp Clin Res*. 2011;12(4):161–3.
- 5 Jakovljevic M. Health expenditure dynamics in Serbia 1995–2012. *Hospital Pharmacology*. 2014;1(3):180–3.
- 6 Alpert MA, Omran J, Bostick BP. Effects of obesity on cardiovascular hemodynamics, cardiac morphology, and ventricular function. *Curr Obes Rep*. 2016 Dec;5(4):424–34.
- 7 Mark DH. Deaths attributable to obesity. *JAMA*. 2005 Apr;293(15):1918–9.
- 8 Di Angelantonio E, Bhupathiraju SN, Wormser D, Gao P, Kaptoge S, Berrington de Gonzalez A, et al.; Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. *Lancet*. 2016 Aug;388(10046):776–86.
- 9 Duncan M, Griffith M, Rutter H, Goldacre MJ. Certification of obesity as a cause of death in England 1979–2006. *Eur J Public Health*. 2010 Dec;20(6):671–5.
- 10 DeMaria EJ. Bariatric surgery for morbid obesity. *N Engl J Med*. 2007 May;356(21):2176–83.
- 11 Neunhaeuserer D, Gasperetti A, Savalla F, Gobbo S, Bullo V, Bergamin M, et al. Functional Evaluation in Obese Patients Before and After Sleeve Gastrectomy. *Obes Surg*. 2017 Dec;27(12):3230–9.
- 12 Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. *Obes Surg*. 2014 Mar;24(3):437–55.
- 13 Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. *BMJ*. 2013 Oct;347 oct22 1:f5934.
- 14 Jakovljevic MB, Milovanovic O. Growing Burden of Non-Communicable Diseases in the Emerging Health Markets: the Case of BRICS. *Front Public Health*. 2015 Apr;3:65–70.
- 15 Bjelović M, Veselinović M. Roux-en-Y gastric bypass. In: Bjelovic M, Polovina M, editors. Surgical treatment of obesity: from bariatric to metabolic surgery. Belgrade: CIBID; 2016. pp. 151–73.
- 16 Okunade AA, Rubin RM, Okunade AK. Delayed Effects of Obese and Overweight Population Conditions on All-Cause Adult Mortality Rate in the USA. *Front Public Health*. 2016 Sep;4:212–21.
- 17 Hsuan CF, Huang CK, Lin JW, Lin LC, Lee TL, Tai CM, et al. The effect of surgical weight reduction on left ventricular structure and function in severe obesity. *Obesity (Silver Spring)*. 2010 Jun;18(6):1188–93.
- 18 Xavier MA, Ceneviva R, Terra Filho J, Sankarankutty AK. Pulmonary function and quality of life in patients with morbid obesity six months after bariatric surgery. *Acta Cir Bras*. 2010 Oct;25(5):407–15.
- 19 Coen PM, Hames KC, Leachman EM, DeLany JP, Ritov VB, Menshikova EV, et al. Reduced skeletal muscle oxidative capacity and elevated ceramide but not diacylglycerol content in severe obesity. *Obesity (Silver Spring)*. 2013 Nov;21(11):2362–71.
- 20 Fleg JL, Piña IL, Balady GJ, Chaitman BR, Fletcher B, Lavie C, et al. Assessment of functional capacity in clinical and research applications: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. *Circulation*. 2000 Sep;102(13):1591–7.
- 21 Nedeljkovic I, Banovic M, Stepanovic J, Giga V, Djordjevic-Dikic A, Trifunovic D, et al. The combined exercise stress echocardiography and cardiopulmonary exercise test for identification of masked heart failure with preserved ejection fraction in patients with hypertension. *Eur J Prev Cardiol*. 2016 Jan;23(1):71–7.
- 22 Dymek MP, Le Grange D, Neven K, Alverdy J. Quality of life after gastric bypass surgery: a cross-sectional study. *Obes Res*. 2002 Nov;10(11):1135–42.

- 23 de Souza SA, Faintuch J, Sant'anna AF. Effect of weight loss on aerobic capacity in patients with severe obesity before and after bariatric surgery. *Obes Surg*. 2010 Jul;20(7):871–5.
- 24 Serés L, Lopez-Ayerbe J, Coll R, Rodriguez O, Vila J, Formiguera X, et al. Increased exercise capacity after surgically induced weight loss in morbid obesity. *Obesity (Silver Spring)*. 2006 Feb;14(2):273–9.
- 25 Wilms B, Ernst B, Thurnheer M, Weisser B, Schultes B. Differential changes in exercise performance after massive weight loss induced by bariatric surgery. *Obes Surg*. 2013 Mar;23(3):365–71.
- 26 Zavorsky GS, Kim DJ, Christou NV. Compensatory exercise hyperventilation is restored in the morbidly obese after bariatric surgery. *Obes Surg*. 2008 May;18(5):549–59.
- 27 Stegen S, Derave W, Calders P, Van Laethem C, Pattyn P. Physical fitness in morbidly obese patients: effect of gastric bypass surgery and exercise training. *Obes Surg*. 2011 Jan;21(1):61–70.
- 28 Kanoupakis E, Michaloudis D, Fraidakis O, Parthenakis F, Vardas P, Melissas J. Left ventricular function and cardiopulmonary performance following surgical treatment of morbid obesity. *Obes Surg*. 2001 Oct;11(5):552–8.
- 29 Browning MG, Franco RL, Herrick JE, Arrowood JA, Evans RK. Assessment of cardiopulmonary responses to treadmill walking following gastric bypass surgery. *Obes Surg*. 2017 Jan;27(1):96–101.
- 30 Vargas CB, Piccoli F, Dani C, Padoin AV, Mottin CC. Functioning of obese individuals in pre- and postoperative periods of bariatric surgery. *Obes Surg*. 2013 Oct;23(10):1590–5.
- 31 Miller GD, Nicklas BJ, You T, Fernandez A, Fernandez A. Physical function improvements after laparoscopic Roux-en-Y gastric bypass surgery. *Surg Obes Relat Dis*. 2009 Sep–Oct;5(5):530–7.
- 32 MacMahon SW, Wilcken DE, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. *N Engl J Med*. 1986 Feb 6;314(6):334–9.
- 33 Alpert MA, Terry BE, Kelly DL. Effect of weight loss on cardiac chamber size, wall thickness and left ventricular function in morbid obesity. *Am J Cardiol*. 1985 Mar;55(6):783–6.
- 34 da Silva RP, Martinez D, Faria CC, de Carli LA, de Souza WI, Meinhardt NG, et al. Improvement of exercise capacity and peripheral metaboreflex after bariatric surgery. *Obes Surg*. 2013 Nov;23(11):1835–41.
- 35 Steele T, Cuthbertson DJ, Wilding JP. Impact of bariatric surgery on physical functioning in obese adults. *Obes Rev*. 2015 Mar;16(3):248–58.
- 36 Egberts K, Brown WA, Brennan L, O'Brien PE. Does exercise improve weight loss after bariatric surgery? A systematic review. *Obes Surg*. 2012 Feb;22(2):335–41.
- 37 Bond DS, Phelan S, Wolfe LG, Evans RK, Meador JG, Kellum JM, et al. Becoming physically active after bariatric surgery is associated with improved weight loss and health-related quality of life. *Obesity (Silver Spring)*. 2009 Jan;17(1):78–83.
- 38 Ohrström M, Hedenbro J, Ekelund M. Energy expenditure during treadmill walking before and after vertical banded gastroplasty: a one-year follow-up study in 11 obese women. *Eur J Surg*. 2001 Nov;167(11):845–50.
- 39 Refsum HE, Holter PH, Løvig T, Haffner JF, Stadaas JO. Pulmonary function and energy expenditure after marked weight loss in obese women: observations before and one year after gastric banding. *Int J Obes*. 1990 Feb;14(2):175–83.
- 40 Babb TG, Korzick D, Meador M, Hodgson JL, Buskirk ER. Ventilatory response of moderately obese women to submaximal exercise. *Int J Obes*. 1991 Jan;15(1):59–65.
- 41 Seidell JC. Societal and personal costs of obesity. *Exp Clin Endocrinol Diabetes*. 1998;106(2 Suppl 2):7–9.
- 42 Tsai AG, Williamson DF, Glick HA. Direct medical cost of overweight and obesity in the USA: a quantitative systematic review. *Obes Rev*. 2011 Jan;12(1):50–61.
- 43 The Guardian. Global cost of obesity-related illness to hit \$1.2tn a year from 2025; [cited 2018 Feb 29] Available from: www.theguardian.com/society/2017/oct/10/treating-obesity-related-illness-will-cost-12tn-a-year-from-2025-experts-warn.
- 44 King WC, Chen JY, Belle SH, Courcoulas AP, Dakin GF, Elder KA, et al. Change in pain and physical function following bariatric surgery for severe obesity. *JAMA*. 2016 Apr;315(13):1362–71.
- 45 Frühbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. *Nat Rev Endocrinol*. 2015 Aug;11(8):465–77.
- 46 Catheline JM, Bihan H, Le Quang T, Sadoun D, Charniot JC, Onnen I, et al. Preoperative cardiac and pulmonary assessment in bariatric surgery. *Obes Surg*. 2008 Mar;18(3):271–7.
- 47 Ding D, Lawson KD, Kolbe-Alexander TL, Finkelstein EA, Katzmarzyk PT, van Mechelen W, et al.; Lancet Physical Activity Series 2 Executive Committee. The economic burden of physical inactivity: a global analysis of major non-communicable diseases. *Lancet*. 2016 Sep;388(10051):1311–24.